Free Trial
NYSE:PLX

Protalix BioTherapeutics 8/7/2023 Earnings Report

Protalix BioTherapeutics logo
$2.84 +0.12 (+4.21%)
As of 01:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protalix BioTherapeutics EPS Results

Actual EPS
$0.21
Consensus EPS
-$0.04
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

Protalix BioTherapeutics Revenue Results

Actual Revenue
$35.08 million
Expected Revenue
$10.22 million
Beat/Miss
Beat by +$24.86 million
YoY Revenue Growth
N/A

Protalix BioTherapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Protalix BioTherapeutics Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Protalix BioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protalix BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protalix BioTherapeutics and other key companies, straight to your email.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX), a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

View Protalix BioTherapeutics Profile

More Earnings Resources from MarketBeat